2010 - TTS International Congress
Clinical Immunosuppression Kidney late
19.16 - The use of cyclosporin A and mycophenolate mofetil 48 hours before renal transplantation enables the use of a low dose cyclosporin and better graft function
Presenter: Hoda, Mamoun, cairo, Egypt
Authors: Soliman A., Mamoun H., Zayed B.
CLINICAL IMMUNOSUPPRESSION - KIDNEY LATE
A.R. Soliman1, H. Mamoun2, B. Zayed2
1Internal Medicine, cairo university, cairo/EGYPT, 2Nephrology, Cairo University, Cairo/EGYPT
Body: Introduction: Reducing calcineurin-inhibitor induced nephrotoxicity and simultaneously avoiding long-term side effects is a desirable goal in renal transplantation. Methods: We examined the hypothesis that using cyclosporin A and mycophenolate mofetil (MMF) 48 hours before renal transplantation would allow lowering the target cyclosporin C2 concentration and have decreasing toxicity and improving graft function. Eighty kidney recipients were enrolled in a single center study comparing two cyclosporin A-based protocols. Group I (n=40) patients received a standard dose cyclosporin (blood cyclosporin C2: 800-1500 ng/ml) with MMF and a standard dose corticosteroid. Group II(n=40)patients were treated with a low-dose cyclosporin (blood cyclosporin C2 concentration 450-800 ng/ml) and MMF, a low dose corticosteroid and induction with cyclosporin A and MMF 48 hours before surgery. Results: Patient (97.5% versus 100%) and graft survival (92.5 versus 95%) at 1 year were not different between groups. Patients of group II experienced significantly less acute rejections than group I (10% versus 30%, p<0.01). Delayed graft function occurred less often in group I than group II but the difference is not significant (17.5 versus 20%, p=NS. Graft function at 1 year was significantly better in group II (serum creatinine 1.31 versus 1.64 mg/dl and creatinine clearance 63 ml/min versus 47 ml/min, p<0.05).Conclusion: We can conclude that a regimen consisting of cyclosporin A and MMF 48 hours before surgery allows safe and efficient use of low target C2 concentration and enable early decrease of cyclosporin dose. These preliminary results indicate a better 1 year graft function compared to a normal dose cyclosporin A regimen.
Disclosure: All authors have declared no conflicts of interest.
You must be logged in to view recordings
By viewing the material on this site you understand and accept that:
- The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
- The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
- The material is solely for educational purposes for qualified health care professionals.
- The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
- The information cannot be used as a substitute for professional care.
- The information does not represent a standard of care.
- No physician-patient relationship is being established.